The present invention relates to prodrug forms of beta-L-1-[5-(E-2-Bromovinyl)-2-(hydroxymethyl)-1,3-dioxolan-4-yl)]uracil (L-BHDU) and their use to treat viral infections of Varicella Zoster Virus, including recurrent VZV (shingles), especially including drug resistant Varicella Zoster Virus and related complications of this viral infection such as rash or post-herpetic neuralgia.

Download PDF
Document Preview
Document History
  • Publication: Jul 23, 2013
  • Application: Nov 8, 2011
    US US 201113291512 A
  • Priority: Nov 8, 2011
    US US 201113291512 A

Download Citation

Sign in to the Lens